INTRANASAL ANTIVIRAL AGENT Russian patent published in 2025 - IPC A61K38/21 A61K31/713 A61K47/20 A61K47/10 A61P31/12 

FIELD: medicine.

SUBSTANCE: invention relates to an intranasal antiviral agent containing recombinant interferon alpha-2b and a natural interferon inducer from the yeast Saccharomyces cerevisiae in the form of a lyophilisate for preparing a solution for intranasal use, and can be used in medicine and pharmaceutics. Intranasal antiviral agent includes interferon, interferon inducer, dimethyl sulphoxide (DMSO) absorption activator, selected from a class of bipolar aprotic solvents and having anti-inflammatory, antiseptic, analgesic action and cryoprotective properties, polyethylene oxide, an antioxidant and a stabilizer. As an interferon inducer – a sodium salt of double-helical ribonucleic acid in the form of a substance, as an interferon – recombinant human interferon alpha-2b, as an antioxidant – Trilon B (EDTA), stabilizer is isotonic sodium chloride solution, and the ratio of dimethyl sulphoxide and double-stranded ribonucleic acid (dsRNA) is 1:4.5.

EFFECT: creation of such an intranasal antiviral agent, which provides intensification of interferon synthesis and antiviral action of the preparation due to the synergistic action of the interferon inducer dsRNA and interferon in a certain ratio, as well as enhanced penetration of active components through cell membranes due to introduction of a suction activator into the composition.

1 cl, 3 dwg, 2 tbl, 4 ex